Inovio Pharmaceuticals (INO) Retained Earnings (2010 - 2026)

Inovio Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting $1.8 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 2.38% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (up 2.38% YoY), while the FY2025 annual figure was $1.8 billion, up 2.25% from the prior year.
• Retained Earnings came in at $1.8 billion for Q2 2026 at Inovio Pharmaceuticals, roughly flat from $1.8 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.8 billion in Q2 2026 to a low of -$1.8 billion in Q3 2025.
• Average Retained Earnings over 5 years is $1.6 billion, with a median of $1.7 billion recorded in 2023.
• Year-over-year, Retained Earnings rose 9.26% in 2022 and slumped 201.9% in 2025.
• Over 5 years, Retained Earnings stood at $1.7 billion in 2022, then increased by 1.76% to $1.7 billion in 2023, then increased by 3.35% to $1.8 billion in 2024, then grew by 2.25% to $1.8 billion in 2025, then gained by 0.3% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $1.8 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.8 billion in Q4 2025.